Company Overview
About Synapticure
Synapticure is a Chicago, Illinois-based virtual care company — backed by Y Combinator with $46.3 million raised including a $25 million Series A led by B Capital in November 2024, with prior investment from CommonSpirit Health, CVS Health Ventures, RA Capital, Google Ventures, Optum Ventures, and Rock Health — providing patients with ALS, Alzheimer's disease, Parkinson's disease, frontotemporal dementia (FTD), Huntington's disease, and other neurodegenerative conditions with specialized virtual neurology care, genetic counseling, AI-powered diagnostic support, care coordination, and 24/7 patient and caregiver support across all 50 US states. Synapticure serves as a nationwide CMS GUIDE (Guiding an Improved Dementia Experience) model provider for Alzheimer's patients — a Centers for Medicare & Medicaid Services innovation program that provides reimbursement for comprehensive dementia care management outside of traditional fee-for-service neurology visits.
Business Model & Competitive Advantage
Synapticure's virtual care model addresses the catastrophic access gap in neurodegenerative disease specialty care: patients with ALS typically wait 6-12 months for an initial appointment at a major academic ALS clinic (Mayo Clinic, Johns Hopkins, MGH), and Alzheimer's patients often receive no specialized care beyond a primary care physician's diagnosis — leaving millions of patients and their caregivers to navigate one of medicine's most complex disease categories without specialist support. Synapticure's platform combines board-certified neurologists (telemedicine visits for diagnosis, medication management, and care planning), genetic counselors (testing for hereditary neurodegenerative disease genes — APOE4 for Alzheimer's, C9orf72 for ALS, LRRK2 for Parkinson's — and counseling families about their risk), AI diagnostic tools (detecting disease progression from speech patterns, gait analysis, and cognitive assessments), and care coordinators who connect patients with clinical trials, disability services, and caregiver respite resources.
Competitive Landscape 2025–2026
In 2025, Synapticure competes in the virtual neurology, neurodegenerative disease management, and specialty telemedicine market with Cala Health (neurological tremor device + care), Biogen's patient support programs (NASDAQ: BIIB, manufacturers of Leqembi for Alzheimer's and Qalsody for ALS), and Included Health (virtual specialty care, $470M raised) for neurodegenerative disease patient and payer contract adoption. The approval of Leqembi (lecanemab, the first disease-modifying Alzheimer's treatment) in 2023 and the ALS drug Qalsody (tofersen) have transformed neurodegenerative disease treatment from purely symptomatic management to active disease modification — dramatically increasing demand for the genetic testing, specialist oversight, and infusion coordination that Synapticure provides. CommonSpirit Health and CVS Health Ventures' strategic investments reflect health system and payer recognition that Synapticure's model can reduce neurodegenerative disease care costs through earlier genetic identification, proactive care coordination, and reduced emergency and hospitalization utilization. The 2025 strategy focuses on scaling the Alzheimer's GUIDE model contract revenue from Medicare/Medicaid payers, growing the genetic counseling for at-risk family members, and building the clinical trial enrollment infrastructure for the drug development companies targeting neurodegenerative diseases.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Synapticure is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Compare Synapticure with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Synapticure? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Synapticure Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Synapticure vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →